Current status and research hotspots of cardio-oncology based on bibliometrics

Background and objective: Cardio-oncology that focuses on the management of cardiovascular toxicity associated with cancer therapy, has grown rapidly worldwide as an emerging interdisciplinary discipline over the past decade. This study aimed to summarize the hot spots and development trends of cardio-oncology to provide a reference for scientific researchers in related fields based on bibliometrics. Methods: CiteSpace was employed to conduct the visualized analysis of annual publications, authors, countries, citations and keywords of the related papers from 2012 to 2022 in the Web of Science Core Collection and China National Knowledge Infrastructure (CNKI). Results: A total of 4 287 English articles and 1 165 Chinese articles were included after screening. At present, the number of foreign literature in the field of cardio-oncology, showed a trend of rapid growth, while our country has "slow development period" and "rapid development period" with 2016 as the boundary. The United States is the country with the largest number of publications in Web of Science, accounting for about 34.21% of the total, followed by China, Italy and other countries. The institutions with the largest number of publications at home and abroad are the University of Texas MD Anderson Cancer Center and the First Affiliated Hospital of Dalian Medical University. Bonnie KY, Ana Barac, Paaladinesh Thavendiranathan are the main contributors abroad, and Xia Yunlong, Zhang Yuhui and Cheng Leilei are the main contributors in China. The most frequently cited literature is the position statement on cancer treatment and cardiovascular toxicity from the European Society of Cardiology. The most frequently used keywords abroad were "heart failure", "breast cancer" and "cardiotoxicity", while the most frequently used keywords in China were "cardiotoxicity", "cardiac tumor" and "doxorubicin". Keywords with the strongest citation bursts at home and abroad in recent three years are "immune checkpoint inhibitors". Conclusion: The research hotspots mainly focus on cardiotoxicity caused by antineoplastic therapy, prevention and treatment, screening and diagnosis of cardiovascular toxicity associated with cancer therapy, etc. Establishing a multidisciplinary diagnosis and treatment model and paying attention to the immune checkpoint inhibitor-related myocarditis and whole process management of cardio-oncology are the directions of future development.